[ad_1]
Profiled investors like Jan Haudemann-Andersen, Runar Vatne, Tore Aksel Voldberg and Ole Martin Halvorsen will benefit from cancer vaccine company Vaccibody’s stock exchange plans on Thursday. The stock, which is listed on the NOTC gray market list, is up 54 percent at the time of writing, giving Haudemann-Andersen a paper profit of NOK 700 million. However, the increase occurs through operations with a relatively low turnover.
On Thursday morning, the company announced a giant deal worth a total of NOK 6.7 billion with Genentech, which is part of the pharmaceutical giant Roche. Vaccibody will also be listed on Mercury Market, around October 7.
It was Agnete Fredriksen who founded the company 13 years ago, along with her supervisor Bjarne Bogen and her fellow teacher Inger Sandlie. She currently works as the scientific director of the company.
Vaccibody has traded in recent weeks at a value of 37 kroner a share on the gray market, according to the NOTC list. On the gray market, the company had a valuation of NOK 10.5 billion before listing today.
Several high-profile shareholders
The company has long been a favorite of several of Norway’s most prominent investors.
- The largest owner is Jan Haudemann-Andersen, who owns around NOK 1.4 billion worth of shares through various Date companies.
- Investor Runar Vatne owns 7.8 million shares of the company through Vatne Equity, which corresponds to 2.75 per cent of the company’s shares. These are valued at approximately NOK 290 million. In addition, it owns 1.5 million shares through Lioness as, two million shares through Leonessa as and 2.5 million shares through Marmori as. In total, Vatne owns around 13.8 million Vaccibody shares.
- Ophthalmologist Ole Martin Halvorsen owns just over eight million shares through OM Holding. This corresponds to 2.87% of the company’s shares and is worth approximately NOK 300 million.
- The investor Tore Aksel Voldberg, for his part, owns just over ten million Vaccibody shares through his investment company Skøien as. His portfolio is worth around NOK 370 million.
When DN last mentioned the company in May, the market value had risen by more than 500 million kronor in three months since the beginning of the year. As of mid-May, the company was valued at NOK 6.8 billion, a price that has risen sharply since then.
Gigantavtale
At the same time that the listing is ready, the company announces that it has signed a global license and collaboration agreement with Genentech, which is part of the Swiss pharmaceutical giant Roche.
The deal lasts for several years, and Vaccibody will receive up to $ 715 million, equivalent to NOK 6.7 billion, including advances and impending installments of $ 200 million, and potential milestone payments of up to $ 515 million, in addition of progressive royalty payments. on the sale of marketed products, it appears from a press release.
– The funds from this agreement will allow us to accelerate and expand the vaccine portfolio, and we believe this will maximize the potential of the company for patients and shareholders. We will also look at possibilities for more licensing and collaboration agreements, including strategic partnerships with a focus on our technology platform, says Michael Engsig, CEO of Vaccibody.(Terms)Copyright Dagens Næringsliv AS and / or our suppliers. We would like you to share our cases via a link, which leads directly to our pages. Copying or other use of all or part of the content may only be done with written permission or as permitted by law. For more terms, see here.
